Nurdati (prolgolimab/nurulimab) / Biocad  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nurdati (prolgolimab/nurulimab) / Biocad
OBERTON, NCT03913923: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Active, not recruiting
2
117
RoW
BCD-217, BCD-100, Placebo
Biocad
Melanoma, Melanoma Metastatic
07/23
12/23

Download Options